Tumor-induced osteomalacia combined with acromegaly: A case report.
acromegaly
case report
octreoscan
phosphate
tumor-induced osteomalacia
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
pubmed:
4
9
2022
medline:
22
11
2022
entrez:
3
9
2022
Statut:
ppublish
Résumé
Both acromegaly and tumor-induced osteomalacia (TIO) are rare diseases caused by an excess hormone secreted by neuroendocrine neoplasms, which are growth hormone (GH) and fibroblast growth factor 23 (FGF23), respectively. GH elevates phosphate reabsorption via the effect of insulin-like factor 1 (IGF-1), while FGF23 inhibits phosphate reabsorption and reduces serum phosphate level markedly. A patient who developed a typical acromegaly appearance but was accompanied with height loss and hypophosphatemia for 2 years visited our hospital. Laboratory investigations showed GH and IGF-1 hypersecretion, as well as hypophosphatemia caused by renal phosphate wasting. Magnetic resonance image revealed a pituitary somatotroph adenoma. Octreoscan scintigraphy also found a causative tumor on the right foot for hypophosphatemia. Then, he underwent resection of the tumor on the right foot. His serum phosphate returned to normal immediately but elevated gradually. Then, we removed the pituitary adenoma of the patient, and the GH and phosphate levels returned to the normal range. Here, we report the first case with acromegaly combined with TIO, the changing process of his phosphate concentration suggests an interesting concurrent effect of excess GH and FGF23 in this rare condition.
Substances chimiques
Insulin-Like Growth Factor I
67763-96-6
Fibroblast Growth Factors
62031-54-3
Phosphates
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-92Informations de copyright
© 2022 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals LLC on behalf of New York Academy of Sciences.
Références
Melmed, S. (2006). Medical progress: Acromegaly. New England Journal of Medicine, 355, 2558-2573.
Tritos, N. A., & Klibanski, A. (2016). Effects of growth hormone on bone. Progress in Molecular Biology and Translational Science, 138, 193-211.
Katznelson, L., Laws, E. R. Jr., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. (2014). Acromegaly: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 99, 3933-3951.
Haffner, D., Grund, A., & Leifheit-Nestler, M. (2021). Renal effects of growth hormone in health and in kidney disease. Pediatric Nephrology, 36, 2511-2530.
Xie, T., Tian, P., Wu, S., Zhang, X., Liu, T., Gu, Y., … Hu, F. (2020). Serum phosphate: Does it more closely reflect the true state of acromegaly? Journal of Clinical Neuroscience, 71, 26-31.
Rokkas, T., Pistiolas, D., Sechopoulos, P., Margantinis, G., & Koukoulis, G. (2008). Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis. World Journal of Gastroenterology, 14, 3484-3489.
Bogazzi, F., Ultimieri, F., Raggi, F., Russo, D., Viacava, P., Cecchetti, D., … Martino, E. (2003). Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 88, 3938-3942.
Ron, E., Gridley, G., Hrubec, Z., Page, W., Arora, S., & Fraumeni, J. F. Jr. (1991). Acromegaly and gastrointestinal cancer. Cancer, 68, 1673-1677.
Gullu, B. E., Celik, O., Gazioglu, N., & Kadioglu, P. (2010). Thyroid cancer is the most common cancer associated with acromegaly. Pituitary, 13, 242-248.
Cohen, O., Schindel, B., & Homburg, R. (1998). Uterine leiomyomata-A feature of acromegaly. Human Reproduction, 13, 1945-1946.
Florenzano, P., Hartley, I. R., Jimenez, M., Roszko, K., Gafni, R. I., & Collins, M. T. (2021). Tumor-induced osteomalacia. Calcified Tissue International, 108, 128-142.
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., … Yamashita, T. (2004). FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research, 19, 429-435.
Li, X., Jiang, Y., Huo, L., Wu, H., Liu, Y., Jin, J., … Xia, W. (2020). Nonremission and recurrent tumor-induced osteomalacia: A retrospective study. Journal of Bone and Mineral Research, 35, 469-477.
Giustina, A., Bronstein, M. D., Chanson, P., Petersenn, S., Casanueva, F. F., Sert, C., … Melmed, S. (2021). International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 106, 3555-3568.
Jiang, Y., Xia, W. B., Xing, X. P., Silva, B. C., Li, M., Wang, O., … Meng, X. W. (2012). Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. Journal of Bone and Mineral Research, 27, 1967-1975.